Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. Issue 6 (16th October 2020)

• Record Type: Journal Article
• Authors: Kaneko, Shun; Tsuchiya, Kaoru; Yasui, Yutaka; Inada, Kento; Kirino, Sakura; Yamashita, Koji; Osawa, Leona; Hayakawa, Yuka; Sekiguchi, Shuhei; Higuchi, Mayu; Takaura, Kenta; Maeyashiki, Chiaki; Tamaki, Nobuharu; Takeguchi, Takaya; Takeguchi, Yuko; Nakanishi, Hiroyuki; Itakura, Jun; Takahashi, Yuka; Himeno, Yoshiro; Kurosaki, Masayuki; Izumi, Namiki
• Is Part Of: JGH open. Volume 4:Issue 6(2020)
• Page Start: 1183
• Page End: 1190
• Publication Date: 2020-10-16
• Subjects: Choi criteria -- hepatocellular carcinoma -- lenvatinib -- modified response evaluation criteria in solid tumors -- response evaluation criteria in solid tumors 1.1
• DOI: 10.1002/jgh3.12420
• Languages: English
• ISSNs: 2397-9070

Abstract

Abstract: Background and Aim: Lenvatinib (LEN) has an antitumor effect with an early reduction in contrast enhancement for unresectable hepatocellular carcinoma (HCC). The aim of this study was to reveal the most useful radiological response evaluation for overall survival (OS) in patients treated with LEN. Methods: Patients receiving LEN therapy ( n = 80) were retrospectively recruited from April 2018 to January 2020. Enhanced computed tomography scans were performed at baseline and every 4–8 weeks. OS and radiological response were evaluated using response evaluation criteria in solid tumors (RECIST 1.1), modified RECIST (mRECIST), and Choi criteria. To be eligible for study, a minimal cumulative duration of LEN was 4 weeks. A total of 62 patients were included in the analysis. Results: The median OS was 469 days. The RECIST 1.1, mRECIST, and Choi criteria identified 14 (22.5%), 30 (48.3%), and 33 (53.2%) patients with an objective response, respectively. In the univariate analysis, Child–Pugh class B, major vascular invasion, and high alpha‐fetoprotein (>200) were statistically significant poor prognostic factors. Radiological response was a significantly better prognostic factor in each criterion (RECIST, mRECIST, and Choi). In the multivariate analysis, radiological response evaluated by RECIST (hazard ratio, 0.259; 95% confidence interval, 0.0723–0.928; P = 0.038) was an independent factor. Furthermore, only RECIST significantly stratified prognosis ( P = 0.041) when limited to the first evaluation. Conclusion: RECIST 1.1 was useful even as early therapeutic evaluation for HCC patients treated with LEN. Understanding the characteristics of radiological response over time may contribute to improving the prognosis of patients with HCC. Abstract : The RECIST 1.1 was a useful, even early, therapeutic evaluation for hepatocellular carcinoma patients treated with lenvatinib. Maintaining relative dose intensity of lenvatinib is crucial after the first evaluation, especially with the mRECIST and Choi criteria, which evaluate staining, in Barcelona Clinic Liver Cancer stage B patients.